Across 28 Phase III heart failure trials, the dataset contains 656 EU/EEA site entries and 18,714 country-level planned participants. Hospital Universitario La Paz is the leading site with participation in 6 of 28 trials, while Spain leads by site count with 100 of 656 site entries and Poland leads by planned participant allocation with 4,741 of 18,714 participants.
The top 10 sites account for 46 site-trial participations. Hospital Universitario La Paz leads with 6 trial participations, equal to 21.4% of the 28-trial cohort. Six of the top 10 sites are in Spain.
| Rank | Site | Country | Trials |
|---|---|---|---|
| 1 | Hospital Universitario La Paz | Spain | 6 |
| 2 | Uniwersytecki Szpital Kliniczny w Poznaniu | Poland | 5 |
| 3 | Hospital Universitari Vall d'Hebron | Spain | 5 |
| 4 | Hospital Clinico Universitario de Valencia | Spain | 5 |
| 5 | ASST Papa Giovanni XXIII | Italy | 5 |
| 6 | Region Skane Skanes Universitetssjukhus | Sweden | 4 |
| 7 | Hospital Universitario y Politecnico La Fe | Spain | 4 |
| 8 | Hospital Universitario Ramon y Cajal | Spain | 4 |
| 9 | Hospital Universitario Puerta de Hierro de Majadahonda | Spain | 4 |
| 10 | Complexo Hospitalario Universitario de Santiago | Spain | 4 |
The site ranking is highly Spain-weighted: Spanish hospitals represent 7 of the 10 highest-frequency institutions, suggesting Spain is a repeat-use heart failure Phase III execution market rather than only a high-volume country in isolated trials.
Spain leads by site count with 100 of 656 site entries, or 15.2%. Poland follows with 96 site entries, France with 91, Italy with 68, Germany with 58, and the Netherlands with 52. Together, the top 6 countries account for 465 of 656 site entries, or 70.9%.
The operational footprint is broad but not evenly distributed. Spain, Poland, France, Italy, Germany, and the Netherlands form the practical core for EU Phase III heart failure site activation.
Poland leads planned participant allocation with 4,741 of 18,714 participants, or 25.3%. Sweden is second with 2,387 participants, followed by France with 1,960 and Germany with 1,515. The top 10 countries account for 16,683 of 18,714 participants, or 89.1%.
| Country | Participants | Share |
|---|---|---|
| Poland | 4,741 | 25.3% |
| Sweden | 2,387 | 12.8% |
| France | 1,960 | 10.5% |
| Germany | 1,515 | 8.1% |
| Spain | 1,279 | 6.8% |
| Netherlands | 1,114 | 6.0% |
| Denmark | 1,080 | 5.8% |
| Bulgaria | 995 | 5.3% |
| Italy | 890 | 4.8% |
| Czechia | 722 | 3.9% |
Spain leads by site footprint, but Poland leads by planned participant allocation. For feasibility, this means site availability and enrollment allocation point to different country priorities.
HFrEF and reduced-ejection-fraction or left-ventricular-systolic-dysfunction trials account for 312 site entries across 7 trials. HFpEF/HFmrEF trials also appear in 7 trials but account for 155 site entries. Acute or decompensated heart failure appears in 6 trials and 83 site entries.
The biggest site footprint is in reduced-ejection-fraction or systolic-dysfunction populations, even though HFpEF/HFmrEF appears in the same number of trials. Site demand is therefore more intense in reduced-EF execution than trial counts alone suggest.
Small molecules dominate the cohort, appearing in 23 of 28 trials, or 82.1%. Monoclonal antibodies appear in 2 trials, peptide/protein/enzyme products in 1 trial, other/non-standard intervention classes in 1 trial, and 1 trial has no specified modality. Combination treatment is used in 12 of 28 trials, or 42.9%.
Phase III heart failure remains predominantly an oral small-molecule execution environment. Site operations should expect standard drug-dispensing workflows more often than infusion- or biologic-heavy infrastructure.
Randomisation is nearly universal, appearing in 27 of 28 trials, or 96.4%. Open-label designs appear in 8 of 28 trials, real-world control in 1 of 28, and recorded stratification factors in 3 of 28. CRO presence is recorded in 15 of 28 trials, or 53.6%.
The cohort is operationally large but methodologically conventional: nearly all trials are randomised, only 1 uses a real-world control, and CRO use passes the 50% mark. Outsourcing demand is therefore tied more to scale and multinational execution than to unusual design mechanics.
Among 27 trials with primary endpoint content, 19 use a composite heart-failure or cardiovascular event primary endpoint, equal to 70.4%. One-primary-endpoint designs dominate: 24 of 27 trials with primary endpoint content have exactly one primary endpoint, or 88.9%. The median number of secondary endpoints is 5.
Heart failure Phase III endpoint strategy is anchored in clinical event composites, especially cardiovascular death, hospitalization, urgent HF visits, and recurrent HF events. KCCQ and functional measures are important but more often appear as secondary or supportive measures than as the primary endpoint.
For Phase III heart failure trials, the strongest execution signal is not a single country but a country-site pattern: Spain supplies the densest repeat-site network, Poland supplies the largest planned participant allocation, and reduced-EF/systolic-dysfunction studies generate the largest site footprint. Operationally, most trials are randomised oral small-molecule studies, while CRO involvement appears in just over half of the cohort.
Prioritise repeat-use Spanish hospitals for network reliability, especially Hospital Universitario La Paz, Vall d'Hebron, La Fe, Ramon y Cajal, and Puerta de Hierro.
Separate site-footprint planning from recruitment-allocation planning: Spain leads the first, while Poland leads the second.
Expect conventional randomised trial operations, event-driven endpoint adjudication, KCCQ support, and predominantly oral small-molecule logistics.